Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Sustaining 2017’s MIPS Success Through 2019

The performance of physicians is measured in several ways, and now they are being rewarded for tangible benchmarks. The Centers for Medicare and Medicaid Services (CMS) is required by law to implement a quality payment incentive program, referred to as the Quality Payment Program (QPP), which rewards practice value and outcomes. As such, the Merit-based Incentive…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The performance of physicians is measured in several ways, and now they are being rewarded for tangible benchmarks.

The Centers for Medicare and Medicaid Services (CMS) is required by law to implement a quality payment incentive program, referred to as the Quality Payment Program (QPP), which rewards practice value and outcomes. As such, the Merit-based Incentive Payment System (MIPS) was designed to tie payments to quality and cost-efficient care, drive improvement in care processes and health outcomes, increase the use of healthcare information and reduce the cost of care. Program participants must report data collected during the calendar year, beginning January 1st and ending December 31st, with data graded in several areas. Data collected in one year must be reported by March 31st of the following year to be eligible for a payment increase and avoid a payment reduction for the next year.

Success of MIPS in 2017

Recently, the CMS published the Quality Payment Program Reporting Experiencereport. Exceeding CMS’s goal of 90% physician participation, the results found that 95% of 1,057,824 eligible clinicians avoided a negative payment adjustment through the 2017 MIPS, with 93% earning a positive payment adjustment. This data is overwhelmingly promising considering 2017 was the first year CMS ran the QPP, making reporting in MIPS’ inaugural performance year an unequivocal successful.

Why You Need to Report

It is essential that physicians continue to participate and report through 2019, as well as each year going forward. Making MIPS reporting habitual will benefit eligible physicians because as the years go by, both the incentives and penalties related to the process will only increase. The highest payment adjustment applied to participants in the 2019 payment year is 1.88%, according to Revcycle Intelligence. Although reporting may become increasingly difficult going forward, it is crucial that as many eligible participants report through MIPS in order to receive a more substantial payment adjustment. Further, reporting above the recommended threshold will pay immense dividends, not only this year but well into the future. CMS stated that in 2017, most participants did, in fact, report more than the minimum—a very positive sign.

How MIPS Works

To better understand how MIPS scores are calculated, the CMS grades physicians on four core performance categories:

  • Quality: This is measured by the quality of care provided to patients by the physician. He or she picks the six measures of performance that best fit their specific practice.
  • Promoting Interoperability: This area assesses the amount of comprehensive and relevant information shared by one clinic with another, including test results and/or summaries.
  • Improvement Activities: This category measures enhancements made to the type of care provided, internal processes or other internal operations throughout a calendar year that keeps a practice current with and or surpasses industry standards and innovations. Much like the quality score, clinics can choose the appropriate activities to report.
  • Cost: The total cost of a typical clinic visit is gauged here and will be calculated based on Medicare claims registered at each specific practice.

Physicians that meaningfully participated in the program, began reporting early in the year and remained motivated in reporting throughout the entire calendar year experienced measurable success

ChartLogic, Invested in Physician Success

At ChartLogic, our mission is to positively impact patient care by delivering award-winning healthcare IT solutions to providers of every size and budget. We offer an ambulatory EHR suite with access to practice management and revenue cycle management services with a system built on understanding workflow and preferences intuitively, facilitating faster note taking and much more. For 25 years, we have been driven by the desire to improve patient care, office efficiency, and profitability for the physician practice. We stay current with technology and legislation that affect our client practices, helping to educate them while encouraging participation in programs that can affect their success. ChartLogic is the physician practice’s true health care partner and we can help your practice become MIPS ready. To learn more about ChartLogic’s vast suite of products and services, you can view our solutions here.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

The FDA’s interchangeable biosimilar pathway is moving from a one-off insulin milestone to a repeatable playbook for pharmacy-level substitution, with Wezlana (ustekinumab-auub) approved as interchangeable to Stelara in late 2023 and a first interchangeable biosimilar to golimumab reported in September 2026. Evidence from a JAMA Health Forum economic evaluation cited by Podiatry Today found that insulin glargine interchangeability in November 2021 was followed by an immediate jump of more than 47,000 prescriptions for Semglee and insulin glargine-yfgn, suggesting the designation itself can change dispensing behavior. For hospitals, health systems, and payers, the operational consequence shows up less in the FDA letter and more in formulary design, NDC-level claims logic, pharmacy notification requirements that vary by state, and the inventory and education workflows that make substitution predictable instead of chaotic.

  • 01Interchangeability is a workflow change, not a clinical debate. The systems that decide spend are NDC mapping, e-prescribe defaults, and pharmacy switch rules governed by state law.
  • 02The pipeline is widening beyond diabetes. Wezlana’s interchangeability to Stelara (Healthcare Purchasing News) and a newly reported interchangeable golimumab biosimilar (Journal of Healthcare Management/AJN via Ovid) signal more specialty and infusion-adjacent categories will face pharmacy-level substitution decisions.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512